Cantor Fitzgerald Believes Emergent Biosolutions (EBS) Won’t Stop Here


In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on Emergent Biosolutions (NYSE: EBS), with a price target of $62. The company’s shares opened today at $56, close to its 52-week high of $60.

Folkes noted:

“Emergent has successfully established itself as a leader in the biodefense field and has carved out a high-barrier-to-entry niche in that market. As investors appreciate the durability and revenue potential of Emergent’s portfolio, we expect upward earnings revisions and multiple expansion to drive the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $62.”

According to TipRanks.com, Folkes is a 1-star analyst with an average return of 0.2% and a 45.2% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Eagle Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $62 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $60 and a one-year low of $32.48. Currently, Emergent Biosolutions has an average volume of 302.7K.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts